January/February 2012 Supplement

Translating Pharmacology to Clinical Effect

Biologic activity is driven by many factors.

KARL G. CSAKY, MD, PHD

View PDF

View Supplement

January/February 2012 Supplement

More from this issue

Recent Supplements

Rising Stars: Yuxi Zheng, MD

Editorially independent supported by Abbvie and Regenxbio

View Insert

One to Watch: Douglas R. Matsunaga, MD

Editorially independent supported by Abbvie and Regenxbio

View Insert

Supporting Patients Throughout Their GA Journey

Editorially Independent Content, Supported With Advertising From Asetllas

View Insert

3 Years After Pegcetacoplan Approval: Addressing Post-Injection Complications and Understanding EZ:RPE Loss as a Potential Measure of Clinical Response

Content Sponsored by Apellis, A subsidiary of Biogen

View Supplement

One to Watch: Alexis Warren, MD

Editorially independent supported by Abbvie and Regenxbio

View Insert

Rising Stars: Jonathan Lin, MD, PhD

Editorially independent supported by Abbvie and Regenxbio

View Insert

Eyetube Retina Series

EYETUBE RETINA MEETING COVERAGE

Translating Pharmacology to Clinical Effect

Biologic activity is driven by many factors.

KARL G. CSAKY, MD, PHD

Within This Issue

Ophthalmic Formulations: Safety and Efficacy of VEGF-neutralizing Drug

The History of Development of Anti-VEGF Agents for Treating Wet AMD